title: Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of Capecitabine--a chemotherapy agent.
abstract: An amphiphile prodrug, 5'-deoxy-5-fluoro-N(4)-(palmityloxycarbonyl) cytidine or 5'-deoxy-5-fluoro-N(4)-(hexadecanaloxycarbonyl) cytidine (5-FCPal), consisting of the same head group as the commercially available chemotherapeutic agent Capecitabine, linked to a palmityl hydrocarbon chain via a carbamate bond is reported. Thermal analysis of this prodrug indicates that it melts at ∼115 °C followed quickly by degradation beginning at ∼120 °C. The neat solid 5-FCPal amphiphile acquires a lamellar crystalline arrangement with a d-spacing of 28.6±0.3 Å, indicating interdigitation of the hydrocarbon chains. Under aqueous conditions, solid 5-FCPal is non-swelling and no lyotropic liquid crystalline phase formation is observed. In order to assess the in vitro toxicity and in vivo efficacy in colloidal form, solid lipid nanoparticles (SLNs) with an average size of ∼700 nm were produced via high pressure homogenization. The in vitro toxicity of the 5-FCPal SLNs against several different cancer and normal cell types was assessed over a 48 h period, and IC(50) values were comparable to those observed for Capecitabine. The in vivo efficacy of the 5-FCPal SLNs was then assessed against the highly aggressive mouse 4T1 breast cancer model. To do so, the prodrug SLNs were administered orally at 3 different dosages (0.1, 0.25, 0.5 mmol/mouse/day) and compared to Capecitabine delivered at the same dosages. After 21 days of receiving the treatments, the 0.5 mmol dose of 5-FCPal exhibited the smallest average tumour volume. Since 5-FCPal is activated in a similar manner to Capecitabine via a 3 step enzymatic pathway with the final step occurring preferentially at the tumour site, formulation of the prodrug into SLNs combines the advantage of selective, localized activation with the sustained release properties of nanostructured amphiphile self-assembly and multiple payload materials thereby potentially creating a more effective anticancer agent.
authors.affiliation: CSIRO Materials Science and Engineering, P.O. Box 184, North Ryde, NSW 1670, Australia.
authors.forename: Xiaojuan
authors.initials: X
authors.lastname: Gong
authors.forename: Minoo J
authors.initials: MJ
authors.lastname: Moghaddam
authors.forename: Sharon M
authors.initials: SM
authors.lastname: Sagnella
authors.forename: Charlotte E
authors.initials: CE
authors.lastname: Conn
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Danon
authors.forename: Lynne J
authors.initials: LJ
authors.lastname: Waddington
authors.forename: Calum J
authors.initials: CJ
authors.lastname: Drummond
mesh_terms: D000818:Animals; D002152:Calorimetry, Differential Scanning; D000069287:Capecitabine; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003102:Colloids; D020285:Cryoelectron Microscopy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D046529:Microscopy, Electron, Transmission; D015394:Molecular Structure; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D011355:Prodrugs / Q000737:chemistry / Q000494:pharmacology*; D053838:Scattering, Small Angle; D013818:Thermogravimetry; D044366:Transition Temperature; D047368:Tumor Burden / Q000187:drug effects; D014867:Water / Q000737:chemistry; D014961:X-Ray Diffraction
chemical_list: D003102:Colloids; D008055:Lipids; D011355:Prodrugs; D014867:Water; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil